News >> News del gruppo >> Eurofins reinforces leadership in the Brazilian testing market

Eurofins reinforces leadership in the Brazilian testing market

Sidebar Image

13 April 2012

Eurofins Scientific, the world leader in food and pharmaceutical products testing, and in environmental laboratory services, has strengthened its position in the Brazilian testing market with the acquisition of ALAC, a leading service provider in the state of Rio Grande do Sul employing over 100 staff.

With the inclusion of ALAC, the Group will extend its expertise in physicochemical analyses in food, feed and environmental testing as well as its microbiology testing capabilities. Further capabilities like occupational health testing services, product testing as well as ecotoxicology will complement the local testing portfolio in Brazil.

Founded in 1991 ALAC holds now a strong position in the food and environmental testing market in the southern region of Brazil. In particular, the scope of accredited tests fits well with Eurofins´ existing capabilities and the integration of these activities should lead to significant synergies and cross selling opportunities.

Comment from Dr. Gilles Martin, Eurofins CEO: "With this acquisition Eurofins takes a leading position in the Brazilian food testing market and further strengthens its share in the environmental analyses segment. It follows the Group's strategy of consolidating the markets where it operates, and taking leadership of those markets."

For further information please contact:

Investor Relations and Corporate Communications

Phone: +32-2-769 7383 +32-2-769 7383


Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics and central laboratory services.

With over 10,000 staff in more than 160 laboratories across 32 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.